Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Annual Meeting of the Western Section of the American Urological Association Meeting being held in Monterey, CA from October 26 to 30, 2008. The podium paper is authored by leading independent clinical research investigators participating in the U.S. clinical trials of NX-1207. NX-1207 is a novel drug developed by Nymox for the treatment of BPH. The drug has been in a number of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that...
[read full story]